More than 2% of the world’s population has fibromyalgia. To combat chronic pain, a French startup has developed an endorphin stimulator, recognized as an “innovative device” in the United States. Soon available for sale?
1.5 billion people suffer from chronic pain worldwide. ” More than half of them are not satisfied with their care “, according to the French startup Remedy Labs. Among them, more than 154 million suffer from fibromyalgia, or about 2% of the world’s population. Their daily ? Diffuse chronic pain, particularly in muscles and joints, significant fatigue or even sleep and cognitive disorders that can hinder their socio-professional life. Complex and misunderstood, this syndrome did not benefit, until now, from any satisfactory treatment. That may be about to change…
An endorphin stimulator
Ahead of the dedicated World Day, May 12, 2022, Remedy Labs announces that it has received, from the Food and drug administration (FDA), the US health agency, the Breakthrough Device designation for its endorphin booster for individual use. This solution stimulates endorphins on demand. Using very high frequency electromagnetic fields, it activates the peripheral nervous system. In response, the brain then releases the one we call ” the hormone of happiness “, a natural pain reliever. ” The first results observed demonstrated a clinically significant improvement in the quality of sleep and the quality of life of the users. », Welcomes the French company in a press release on May 5, 2022.
A major cost to society
This new non-drug approach aims to improve the quality of life of the ten million Americans affected by this pathology, which represents a major cost for patients but also for society. The direct and indirect costs are estimated at 180 billion dollars per year in the United States, representing a loss close to one percent of global productivity.
” The safety of our endorphin stimulator was clinically validated in 2018explains Remedee labs. Investigating Centers are currently evaluating its effectiveness through clinical trials for various specific therapeutic applications including rheumatic pain and migraine. » In the meantime, the recognition of the FDA constitutes a major stage for an authorization of placing on the American market… What about Europe, which gathers 14 million fibromyalgia?
“All reproduction and representation rights reserved. © Handicap.fr. This article was written by Cassandre Rogeret, Handicap.fr journalist”